title: Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials.
abstract: OBJECTIVE
  Canagliflozin has been proposed as an effective treatment for type 2 diabetes. This meta-analysis of randomized control trials aimed to evaluate the effect of canagliflozin combined with other hypoglycemic drugs.
  
  
  METHODS
  We searched Medline, Embase, Cochrane Library, Google Scholar and ClinicalTrials.gov for randomized control trials comparing canagliflozin combined with conventional antidiabetic drugs vs placebo. Our main end-points were glycemic control and change in weight. We assessed pooled data by use of a random-effects model.
  
  
  RESULTS
  Of 161 identified studies, six were eligible and were included in our analysis (n = 4670 participants). Compared with the placebo, mean changes in glycosylated hemoglobin were -0.60% (95% confidence interval -0.67 to -0.54%; I (2) = 0%) for canagliflozin 100 mg, and -0.76% (95% confidence interval -0.84 to -0.68%; I (2) = 20%) for canagliflozin 300 mg with bodyweight loss.
  
  
  CONCLUSIONS
  Canagliflozin as an add-on drug to other antidiabetic drugs effectively lowers blood glucose without significant weight gain.
authors.affiliation: Department of Medical Section for Cadres First Affiliated Hospital of Kunming Medical University Kunming China.
authors.forename: Qi
authors.identifier: 0000-0001-9360-0395
authors.initials: Q
authors.lastname: Meng
authors.affiliation: Department of Medical Section for Cadres First Affiliated Hospital of Kunming Medical University Kunming China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Shen
authors.affiliation: Department of Epidemiology School of Public Health Peking University Beijing China.
authors.forename: Dajin
authors.initials: D
authors.lastname: Liu
authors.affiliation: Department of Medical Section for Cadres First Affiliated Hospital of Kunming Medical University Kunming China.
authors.forename: Fei
authors.initials: F
authors.lastname: Jiang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001835:Body Weight; D000068896:Canagliflozin / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D000068896:Canagliflozin
keywords: Canagliflozin; Meta‐analysis; Type 2 diabetes mellitus